Researcher from Johns Hopkins University Details New Studies and Findings in the Area of Cutaneous T-Cell Lymphoma (Mogamulizumab Multimodality Therapy with Systemic Retinoids, Interferon, or Extracorporeal Photopheresis for Advanced Cutaneous...).

A recent study conducted by researchers at Johns Hopkins University explores the use of mogamulizumab, a monoclonal antibody, in combination with other therapies for the treatment of cutaneous T-cell lymphoma (CTCL). The study found that the combination therapy resulted in positive treatment responses and durable outcomes for patients, with minimal adverse effects. The researchers suggest that this multimodality approach warrants further investigation and confirmation. This information may be valuable for individuals researching CTCL and seeking alternative treatment options. [Extracted from the article]